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Three 1-methoxy analogs of CP-47,497 (7, 8 and 19) have been synthesized and their affinities 
for the cannabinoid CB1 and CB2 receptors have been determined. Although these compounds 
exhibit selectivity for the CB2 receptor none have significant affinity for either receptor. 
Modeling and receptor docking studies were carried out, which provide a rationalization for the 




The modern era of the study of cannabinoids began with the elucidation of the structure of the 
principal psychoactive ingredient in marijuana, Δ9-tetrahydrocannabinol (Δ9-THC, 1), by Gaoni 
and Mechoulam.1 Subsequently, a number of analogs of 1 were synthesized and comprehensive 
structure-activity relationships (SAR) were developed based upon the Δ9-THC template.2-4 In the 
course of the development of analgesics derived from the potent synthetic cannabinoid, (-)-9-
nor-9β-hydroxyhexahydrocannabinol (HHC, 2), a series of structurally modified analogs of 2 
were prepared.5-7 Although useful analgesics were not developed, a series of non-traditional 
cannabinoids was developed in which the oxygen containing pyran ring of THC was removed to 
provide a bicyclic system that retained the phenolic hydroxyl group of THC and the 9-hydroxyl 
of HHC.8 The SAR for traditional cannabinoids specifies maximum potency with a 1,1-
dimethylheptyl substituent at the 3-position of the aromatic ring and an equatorial β-orientation 
of the 9-hydroxyl group.8 These SAR are also valid for these bicyclic non-traditional 
cannabinoids and the least complex molecule that fulfilled these requirements was CP-47,497 (3, 
DMH = 1,1-dimethylheptyl), which was found to be more potent than THC in vivo. A 
hydroxypropyl group at C-4 of the cyclohexanol ring, as in CP-55,940 (4), led to enhanced 
potency and in 1988 [3H]-CP-55,940 was employed by Howlett's group to identify a cannabinoid 
receptor in rat brain.9 This G-protein-coupled, transmembrane receptor is now designated as the 
CB1 receptor and is expressed primarily in the central nervous system.10-12 
 
 
In 1993 Munro et al. identified a second receptor in macrophages present in the spleen.13 This 
receptor, designated CB2, is expressed primarily in the in the immune system and it has been 
suggested that it is responsible for the immunomodulatory effects of cannabinoids,14-19 a 
conclusion that is supported by the fact that these effects are absent in CB2 receptor knockout 
mice.19 There is increasing evidence that the endocannabinoid system is of very considerable 
physiological significance. In particular, CB2 receptors are expressed in C6 glioma cells20 and 
both CB1 and CB2 receptors are expressed in non-melanoma skin cancer cells.21 There is also a 
considerable body of evidence that the CB2 receptor is involved in inflammatory pain22-29 Two 
recent reviews have pointed out the potential of the endocannabinoid system as a therapeutic 
target and suggest that developing new, selective ligands for the CB2 receptor may lead to the 
development of new useful drugs for the treatment of a number diseases.30,31 
 
Several years ago we developed a series of 1-deoxy-Δ8-THC analogs, several of which are highly 
selective for the CB2 receptor.32 One of these compounds, JWH-133 (5) is a full agonist at the 
CB2 receptor, has 200-fold selectivity for the receptor and is inactive in the mouse model of 
cannabinoid activity.33 This series of compounds was developed in analogy with 1-deoxy-3-(1,1-
dimethylheptyl)-Δ8-THC, which is a moderately selective CB2 receptor ligand.32,34 Based upon 
the observation that 1-deoxy-Δ8-THC analogs are highly selective ligands for the CB2 receptor, 
we hypothesized that 1-deoxy analogs of CP-47,497 (3) and CP-55,940 (4) would also exhibit 
useful selectivity for the CB2 receptor and series of 1-deoxy analogs of both compounds was 
synthesized and their pharmacology evaluated.35 In contrast to our hypothesis, none of these 
compounds have more than modest affinity for either the CB1 or CB2 receptor. It appeared 
possible that the failure of these compounds to bind to either receptor was due to the lack of the 
oxygen atom at C-1 that was present in the Pfizer compounds and we have now synthesized 1-
methoxy analogs of CP-47497 (6) and determined their affinity for the CB1 and CB2 receptors. 
 
RESULTS 
Typically 1-deoxy and 1-methoxy THC analogs with the highest affinity for both the CB1 and 
CB2 receptors are those with a 3-dimethylhexyl or dimethylheptyl substituent32,36 and 
consequently it was determined that 1-methoxy-9β-hydroxy dimethylhexyl (7) and 
dimethylheptyl (8) CP-47,497 analogs would be the initial synthetic targets (Scheme 1). If either 
of these compounds exhibited interesting pharmacology, other compounds in this series were to 
be investigated. 
 
The synthesis of the methoxy analogs of CP-47497 as illustrated in Scheme 1 is a modification 
of the method employed for the synthesis of the 1-deoxy analogs, however using 2-(4-bromo-3-
methoxyphenyl)-2-methylheptane (9) and 2-(4-bromo-3-methoxyphenyl)-2-methyloctane (10) as 
starting materials rather than the dimethylalkylbenzenes used for the deoxy analogs.35 We used 
aryl bromide 10 a number of years ago in the synthesis of 1-deoxy-11-hydroxy-3-(1,1-
dimethylheptyl)-Δ8-THC37 and employed a modification of that synthesis in the present work. 
 
Scheme 1: Reagents and conditions: (a) NaSPr, DMF, reflux; (b) (EtO)2PO, CCl4, Et3N, 25 °C; 
(c) Li, NH3, -78 °C; (d) Br2, HOAc, 25 °C; (e) n-BuLi, THF -78 °C; (f) 3-Ethoxy-2-cyclohexen-
1-one, THF, reflux, then 10% HCl, 25 °C; (g) Li, NH3, THF, -78 °C; (h) NaBH4, EtOH, 0–25 




As described previously,37 Selective demethylation of one of the methoxy groups of 2-(3,5-
dimethoxyphenyl)-2-methylheptane (11) and 2-(3,5-dimethoxyphenyl)-2-methyloctane (12) 
using sodium thiopropoxide followed by conversion of the phenol to the corresponding diethyl 
phosphate and reduction with lithium in ammonia afforded 2-(3-methoxyphenyl)-2-
methylheptane (13) and 2-(3-methoxyphenyl)-2-methylheptane (14). Reaction of compounds 13 
and 14 with bromine in acetic acid provided aryl bromides 9 and 10.37 The corresponding 
aryllithiums were prepared via halogen-metal interconversion38 from bromides 9 and 10 using n-
butyllithium, which were reacted with 3-ethoxycyclohex-2-en-1-one to provide the 
corresponding tertiary alcohol. Treatment of the crude reaction products with dilute HCl resulted 
in hydrolysis of the enol ether, which eliminated the elements of water to provide 3-
arylcyclohexenones 15 and 16. Lithium ammonia reduction of these cyclohexenones gave 3-
arylcyclohexanones 17 and 18.39 Sodium borohydride reduction40 of 17 and 18 gave respectively 
(1R*,3S*)3-[2-methoxy-4-(1,1-dimethylhexyl)phenyl]cyclohexanol (7, JWH-440) and 
(1R*,3S*)3-[2-methoxy-4-(1,1-dimethylheptyl)phenyl]cyclohexanol (8, JWH 441).41 Both of 
these compounds are racemic as indicated by the notation R* and S*, which indicate relative 
stereochemistry.41 The equatorial stereochemistry of the hydroxyl group in alcohols 7 and 8 was 
assigned based upon the method of synthesis40 and the 1H NMR spectrum in which the carbinol 
proton appears as a multiplet centered about δ 3.79, which is characteristic of an axial carbinol 
proton.42 
 
The affinities of alcohols 7 (JWH-440) and 8 (JWH-441) for the CB1 receptor were determined 
by measuring their ability to displace the potent cannabinoid [3H] CP-55,940 from its binding 
site in a membrane preparation from rat brain as described by Compton et al.44 Affinities for the 
CB2 receptor were determined by measuring the ability of the compounds to displace [3H] CP-
55,940 from a cloned human receptor preparation using the procedure described by Showalter et 
al.45 The results of these determinations are summarized in Table 1. Also included in Table 1 are 
the receptor affinities for Δ8-THC (1) and CP-47,497 (3). 
  
As shown in Table 1, both JWH-440 (7) and JWH-441 (8) have little affinity for either the CB1 
or CB2 receptor. Since it was conceivable that the stereochemistry of the secondary hydroxyl 
group may have affected the interaction of JWH-440 or JWH-441 with the receptors, ketone 17 
was reduced with L-Selectride, a reagent that stereoselectively reduces cyclic ketones to the 
corresponding axial alcohol,43 to provide racemic (1S*,3S*)3-[2-methoxy-4-(1,1-
dimethylhexyl)phenyl]cyclohexanol (19, JWH-442), which has an axial hydroxyl substituent. 
The 1H NMR spectrum of this compound is consistent with the assigned stereochemistry, with 
the equatorial carbionol proton as a broadened singlet at δ 4.24.42 This methoxy CP-47,497 
analog also has negligible affinity for either the CB1 or CB2 receptor (Table 1). 
 
Table 1: Receptor affinities (mean ± SEM) of CP-47,497 analogs (7, 8, 19, 20, and 21), Δ9-THC 
(1) and CP-47,497 (3) 
Compound Ki (nM) 
 CB1 CB2 CB1/CB2 
Δ9-THC (1) 41 ± 2a 36 ± 10b 1.1 
CP-47,497 (3) 9.54 ± 0.35a ND  
JWH-440 (7) 4414 ± 693 553 ± 32 8.0 
JWH-441 (8) >10,000 808 ± 123 >12 
JWH-442 (19) 4123 ± 1319 693 ± 80 5.9 
JWH-324 (20) 2954 ± 191c 231 ± 48c 13 
JWH-342 (21) 645 ± 29c 178 ± 15c 3.6 
aRef. 44. bRef. 45. cRef. 35. 
 
In order to provide a rationale for the failure of not only compounds 7, 8, and 19 but also the 
deoxy CP-47,497 analogs we reported previously35 to have appreciable affinity for either 
receptor, a modeling and receptor docking study was carried out. This study included JWH-441 
(8), JWH-324, (1R*,3S*)3-[4-(1,1-dimethylheptyl)phenyl]cyclohexanol (20) and JWH-342, 
(1S*,3S*)3-[4-(1,1-dimethylheptyl)phenyl]cyclohexanol (21). The affinities of compounds 20 




CB2 Docking Studies 
The minimized structure of each ligand was docked in the refined model of the CB2 receptor in 
its activated state (R*) in the same binding site as described for AM841 (22).46 This CB2 
receptor model includes the extracellular and intracellular domains, as well as the 
transmembrane helix (TMH) bundle. JWH-324 (20), JWH-342 (21) and JWH-441 (8) have low 
CB2 affinities (JWH-324, Ki = 231 nM; JWH-342, Ki = 178 nM; and JWH-441 Ki = 808 nM). It 
was found that a significant conformational energy expense is required for each of these ligands 
to dock in an AM841-like conformation at CB2 R*. For all three ligands, this expense includes a 
required re-orientation of the dimethylheptyl side chain, as well as a change in the C1-C1a-C10a-
C10 torsion angle, which affects the relative orientation of the A and C rings. A reorientation of 
the methoxy group is also required for JWH-441 (8) and this additional expense may be the 
reason for the very low CB2 affinity of this compound. Figure 1 (A-C) illustrate the 
conformational differences between the global minimum energy conformers of JWH-324, JWH-
342 and JWH-441 (shown in green) and the final docked conformation of each ligand at CB2 
(shown in orange). For JWH-324 (20), the C1-C1a-C10a-C10 torsion angle must shift from its 
global minimum position of -117° to 15°(see Figure 1A, orange). The total conformational cost 
for the ligand to dock at CB2 R* is 5.3 kcal/mol. In addition to Van der Waals interactions with 
residues that line its CB2 R* binding site, JWH-324 (20) can form a hydrogen bond with S7.39 
(O-O distance = 2.62 Å; O-H--O angle = 170°) (see Figure 2A). The total interaction energy for 
JWH-324 (20) at CB2 R* was found to be -36.3 kcal/mol. For JWH-342 (21), the C1-C1a-C10a-
C10 torsion angle must shift from its global minimum position of -116° to -48° (see Figure 1B, 
orange). The total conformational cost for the ligand to dock at CB2 R* is 6.5 kcal/mol. In this 
conformation, JWH-342 (21) can form a hydrogen bond with S7.39 (O-O distance = 2.62 Å; O-
H--O angle = 168°) (see Figure 2B). Although JWH-342 (21) incurs a higher energy expense 
relative to JWH-324 (20) to dock with CB2 R*, JWH-342 (21) compensates for this higher 
energy expense with greater Van der Waals interactions, particularly with S6.58 and A7.36, 
leading to an overall interaction energy (-37.3 kcal/mol) that is just slightly better than that of 
JWH-324 (20). For JWH-441 (8), it should be noted that the global minimum energy position of 
the dimethylheptyl side chain differs from that in JWH-324 (20) and JWH-342 (21). In these 
ligands one of the methyl groups is in the plane of the aromatic ring, pointing up (see Figures 
1A-B, green). In JWH-441, steric repulsion from the methoxy group on Ring C, causes the 
methyl to point down, but the methyl does remain in the plane of the aromatic ring (see Figure 
1C, green). For JWH-441 (8), the C1-C1a-C10a-C10 torsion angle must shift from its global 
minimum position of -117° to 10° and the Ring C methoxy group has to shift 106° out of plane 
with Ring C (see Figure 1C, orange) to avoid steric interference with L6.54, S6.58, S7.39 or the 
ligand's A ring. The total conformational cost for the ligand to dock at CB2 is quite high at 10.4 
kcal/mol. In addition to Van der Waals interactions with residues that line its binding site, JWH-
441 (8) can form a hydrogen bond with S7.39 (O-O distance = 2.67 Å; O-H--O angle = 171°) 
(see Figure 2C). The total interaction energy for JWH-441 (8) at CB2 was found to be -32.6 
kcal/mol. Thus, while each of these ligands can establish some interaction at CB2, the 
conformational energy expense incurred when each binds to CB2 will significantly impact the 
affinity of each. These results are consistent with the CB2 affinities for these compounds listed in 
Table 1. 
 
Figure 1: A comparison of the global minimum energy conformation (green) vs. the docked 
conformation (orange) of JWH-324(20), JWH-342(22) and JWH-441(8) at CB2 R* is illustrated 
here. The conformers have been overlaid on their phenyl rings (Ring C) and are oriented so that 
the phenyl ring (Ring C) is perpendicular to the plane of the page, with the dimethylheptyl side 
chain closest to the viewer and the carbocyclic ring (Ring A) furthest from the viewer (A) For 
JWH-324 (20), the C1–C1a–C10a–C10 torsion angle must shift from its global minimum 
position of -117° to 15°. The conformational energy difference between the two conformers 5.3 
kcal/mol. (B) For JWH-342 (21), the C1–C1a–C10a–C10 torsion angle must shift from its global 
minimum position of -116° to -48°. The total conformational cost for the ligand to dock at CB2 
is 6.5 kcal/mol. (C) For JWH-441 (8), the C1–C1a–C10a–C10 torsion angle must shift from its 
global minimum position of -117° to 10° and the Ring C methoxy group has to shift 106° out of 
plane with Ring C to avoid steric interference with L6.54, S6.58, S7.39 or the ligand’s A ring. 






Figure 2: JWH-324 (20), JWH-342 (21) and JWH-441(8) are shown here docked at a model of 
the CB2 activated (R*) state. The view in each case is from the lipid bilayer, between TMH2 and 
TMH7 (TMH1 has been omitted for clarity). (A) For JWH-324 (20), in addition to Van der 
Waals interactions with residues that line its binding site, the ligand can form a hydrogen bond 
with S7.39 (O–O distance = 2.62 Å; O–H–O angle = 170°). The total interaction energy for 
JWH-324 (20) at CB2R∗ was found to be −36.3 kcal/mol. (B) For JWH-342 (21), the ligand can 
form a hydrogen bond with S7.39 (O–O distance = 2.62 Å; O–H–O angle = 168°). Although 
JWH-342 (21) incurs a higher energy expense relative to JWH-324 (20) to dock with CB2R∗, 
JWH-342 (21) compensates for this higher energy expense with greater Van der Waals 
interactions, particularly with S6.58 and A7.36, leading to an overall interaction energy 
(−37.3 kcal/mol) that is just slightly better than that of JWH-324 (20). (C) For JWH-441(8), in 
addition to Van der Waals interactions with residues that line its binding site, the ligand can form 
a hydrogen bond with S7.39 (O–O distance = 2.67 Å; O–H–O angle = 171°). The total 




CB1 Docking Studies 
The minimized structure of each ligand was docked in the refined model of the CB1 receptor 
activated (R*) state in the same binding site as described for HU-210.47 This CB1 receptor model 
includes a truncated N-terminus, all extracellular loops and intracellular domains, as well as the 
transmembrane helix bundle. JWH-324 (20), JWH-342 (21) and JWH-441 (8) have 
low/essentially no CB1 affinity (JWH-324, Ki = 2954 nM; JWH-342, Ki = 645 nM; and JWH-
441 Ki > 10,000 nM). Docking studies showed that the A ring in all three ligands has severe Van 
der Waals overlaps with S7.39 or K3.28 when docked in the HU-210 binding site at CB1. In 
addition, the C ring methoxy group of JWH-441 has severe Van der Waals overlaps with V3.32, 
L6.51 and C7.42 or, if the C ring is rotated 180°, the methoxy group has severe Van der Waals 
overlaps with F2.57 and L7.43. 
 
DISCUSSION 
These methoxy CP-47,497 analogs were designed in analogy to 1-methoxy-3-(dimethylhexyl 
and dimethylheptyl)-Δ8-THC, which exhibit respectively 174 and 12-fold selectivity for the CB2 
receptor.36 Both these compounds have from good to high affinity for the CB2 receptor (Ki = 18 
and 57 nM, respectively). Also, both epimers of the secondary hydroxyl groups of the 
corresponding 11-nor-9-hydroxy-hexahydrocannabinols, which have from 4.5 to 33-fold 
selectivity for the CB2 receptor, served as templates for the methoxy CP-47,497 analogs.42 These 
compounds have from 12 nM to 38 nM affinity for the CB2, In earlier work, we synthesized 1-
deoxy analogs of CP-47,497.35 Although all of these compounds exhibit varying degrees of 
selectivity for the CB2 receptor, only the dimethylheptyl and the dimethyloctyl analogs with 
axial hydroxyl groups have affinity for the CB2 receptor greater than 200 nM. In that publication 
it was suggested that an oxygen substituent on the aromatic ring was probably necessary for CB2 
receptor binding. This hypothesis led us to the preparation of the methoxy CP-47,497 analogs 
described above. 
 
It is apparent from the experimentally determined receptor binding data that, although the 
hypothesis that an oxygen substituent on the aromatic ring was necessary for CB2 binding 
appeared to be eminently reasonable, the lack of affinity of methoxy CP-47,497 analogs JWH-
440 (7), JWH-441 (8) and JWH-442 (19) for the CB2 receptor indicates that this hypothesis is 
not correct. In order to provide a rationale for the lack of affinity of not only the methoxy CP-
47,497 analogs as well as the deoxy CP-47,497 analogs reported previously,35 molecular 
modeling and docking studies were carried out for deoxy analogs JWH-324 (20), JWH-342 (21) 
and methoxy analog JWH-441 (8). These three compounds have negligible affinity for the CB1 
receptor and the docking studies indicate that the saturated carbocyclic ring of these compounds 
has severe steric clashes with serine 7.39 and lysine 3.28 of the CB1 receptor. In addition the 
methoxy group of JWH-441 (8) has severe clashes with valine 3.32, leucine 6.51 and cysteine 
7.42. Rotation of the aromatic ring leads to alternative steric clashes with phenylalanine 2.57 and 
leucine 7.43. These severe steric clashes of these compounds with the amino acids of the CB1 
receptor are consistent with the very weak CB1 receptor affinities of JWH-441 (8), JWH-324 
(20) and JWH-342 (21). 
 
The two 1-deoxy CP-47,497 analogs, JWH-324 (20) and JWH-342 (21) both have modest 
affinities for the CB2 receptor (231 ± 48 and 178 ± 15 nM, respectively). For docking of these 
two compounds with the CB2 receptor model, rotation about the C1a-C10a bond between the 
aromatic and saturated rings is necessary as well as a reorientation of the dimethylheptyl side 
chain. The conformational energy expense is 5.3 kcal/mol for JWH-324 (20) and 6.5 kcal/mol 
for JWH-342 (21). In the case of methoxy analog JWH-441 (8) in addition to reorientation of the 
dimethylheptyl side chain and rotation of the C1a-C10a bond, the methoxy group must rotate out 
of the plane of the aromatic ring. This results in a conformational energy expense of 10.4 
kcal/mol. The overall interaction energies of JWH-324 (20), JWH-342 (21) and JWH-441 (8) at 
CB2 were found to be -36.3 kcal/mol, -37.3 kcal/mol and -32.6 kcal/mol, respectively. The trend 
in interaction energies, JWH-342 (21) < JWH-324 (20) <JWH-441 (8) is consistent with the 
trend in average Ki vallues for these ligands at CB2. However, the interaction energy of JWH-
342 (21) is only 1.0 kcal/mol better than that of JWH-324 (20). This small difference is also 
consistent with the fact that the Ki values of these two compounds have slightly overlapping 
ranges when experimental error is taken into account. 
 
CONCLUSIONS 
A priori it appeared that 1-deoxy and 1-methoxy analogs of the very potent bicyclic Pfizer non-
traditional cannabinoids would provide compounds that were selective ligands for the CB2 
receptor, just as various similar analogs of Δ8-THC (1) and 11-nor-9-
hydroxyhexahydrocannabinol (2) have good CB2 receptor affinity with little affinity for the CB1 
receptor. However, the lack of significant affinity for these analogs of CP-47,497 indicates that 
this hypothesis is not correct. CP-47,497 and related compounds have a phenolic hydroxyl group, 
which permits energetically significant hydrogen bonding interactions with the receptors, which 
are lacking in the deoxy and methoxy analogs. It appears that the rigid structure of the 
dibenzopyran system of the classical cannabinoids that provided the nucleus of the CB2 selective 
ligands based upon that template provides a superior platform for the synthesis of structurally 




1H and 13C NMR spectra were recorded on Bruker 300AC and JEOL 500 spectrometers. Mass 
spectral analyses were performed on a Shimadzu QP2010 capillary gas chromatograph/mass 
spectrometer equipped with a mass sensitive detector at 1.01 kV. HRMS data were obtained in 
the Mass Spectrometry Laboratory, School of Chemical Sciences, University of Illinois. Ether 
and THF were distilled from Na-benzophenone ketyl immediately before use, and other solvents 
were purified using standard procedures. Column chromatography was carried out on Sorbent 
Technologies silica gel (32 - 63 μ) using the indicated solvents as eluents. All new compounds 
were homogeneous to TLC and 13C NMR. All target compounds were homogeneous to GLC or 
TLC in two different solvent systems and GLC. TLC was carried out using 200 μm silica gel 
plates with the indicated solvents. 
 
2-(3-Methoxy-5-hydroxyphenyl)-2-methylheptane 
To a suspension of 1.4 g (34 mmol, 60% dispersion in oil) of NaH in 14 mL of dry DMF under 
argon, was added dropwise 4.2 mL (46 mmol) of 1-propanethiol, and the reaction was stirred for 
30 min at ambient temperature. To this mixture was added 1.32 g (5.28 mmol) of 2-(3,5-
dimethoxyphenyl)-2-methylheptane32 (11) in 7 mL of dry DMF, and the resultant solution was 
heated at reflux for 5 h, cooled to ambient temperature and poured into 40 mL of 1 M HCl. The 
solution was extracted with three portions of ether and the ethereal extracts were washed with 
successive portions of aqueous NaHCO3, brine, dried (MgSO4) and concentrated in vacuo. The 
crude product was purified by flash chromatography (petroleum ether/ether, 8:2) to afford 0.96 g 
(77%) of 2-(3-methoxy-5-hydroxyphenyl)-2-methylheptane as a colorless oil; 1H NMR (500 
MHz, CDCl3) δ 0.81 (t, J = 7.0 Hz, 3H), 0.97-1.15 (m, 2H), 1.16-1.24 (m, 4H), 1.26 (s, 6H), 1.56 
(t, J = 6.0 Hz, 2H), 3.79 (s, 3H), 6.28 (s, 1H), 6.36 (s, 1H), 6.45 (s, 1H); 13C NMR (125.77 MHz, 
CDCl3) δ 14.1, 22.7, 24.5, 28.7, 32.6, 37.6, 44.5, 55.6, 96.6, 105.2, 105.9, 152.9, 156.1, 160.2; 
MS (EI) m/z (rel intensity) 121 (37), 149 (100), 236 (60). 
 
2-(3-Methoxyphenyl)-2-methylheptane (13) 
To a solution of 1.56 g (6.61 mmol) of 2-(3-hydroxyphenyl-5-methoxyphenyl)-2-methylheptane 
and 1.08 mL (8.42 mmol) of diethyl phosphite in 4 mL of CCl4 at 0 °C was added dropwise 1 
mL (7.17 mmol) of triethylamine. The solution was stirred at 0 °C for 1 h, allowed to warm to 
ambient temperature and stirred for 7 h at ambient temperature. The mixture was diluted with 
CH2Cl2 and washed with successive solutions of H2O, 1 M aqueous NaOH, H2O, 1 M HCl, and 
H2O. The organic layer was dried (MgSO4), concentrated in vacuo and purified by flash 
chromatography (petroleum ether/ether, 7:3) to give 2.01 g (93%) of 2-(3-hydroxyphenyl-5-
methoxyphenyl)-2-methylheptane diethyl phosphate as a red oil, which was used in the next step 
without further purification:1H NMR (500 MHz, CDCl3) δ 0.82 (t, J = 7.0 Hz, 3H), 0.98-1.14 
(m, 2H), 1.15-1.25 (m, 4H), 1.27 (s, 6H), 1.39 (t, J = 7.1 Hz, 6H), 1.56 (t, J = 6.0 Hz, 2H), 3.79 
(s, 3H), 4.21-4.26 (m, 4H), 6.64 (s, 1H), 6.71 (s, 1H), 6.78 (s, 1H); 13C NMR (125.77 MHz, 
CDCl3) δ 13.9, 15.9, 16.8, 22.6, 24.6, 28.6, 31.7, 37.6, 44.3, 55.5, 102.2, 102., 109.2, 
109.9,151.3,152.7, 160.1; MS (EI) m/z (rel intensity) 245 (60), 273 (30), 302 (100), 372 (50). 
 
To 49 mL of liquid NH3 at -78 °C was added 0.052 g (7.49 g atom) of lithium shot and the 
solution was stirred for 15 min. A solution of 0.83 g (2.23 mmol) 2-(3-hydroxyphenyl-5-
methoxyphenyl)-2-methylheptane diethyl phosphate in 10 mL of dry THF was added dropwise, 
and the reaction was stirred at -78°C for 3 h. The reaction was quenched by the addition of solid 
NH4Cl and the NH3 was evaporated overnight at ambient temperature. The solid residue was 
taken up in 15 mL of H2O and extracted with two portions of ether. The ethereal extracts were 
washed with 10 % aqueous HCl and brine, dried (MgSO4), and the solvent removed in vacuo. 
The yellow oil was purified by flash chromatography (petroleum ether/ether, 9:1) to give 0.35 g 
(78%) of 13 as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H), 0.97-1.11 
(m, 2H), 1.12-1.25 (m, 4H), 1.26 (s, 6H), 1.57 (t, J = 6.0 Hz, 2H), 3.81 (s, 3H), 6.69-6.72 (m, 
1H), 6.88-6.91 (m, 2H), 7.18-7.23 (m, 1H); 13C NMR (125.77 MHz, CDCl3) δ 14.1, 22.7, 24.6, 
28.9, 32.6, 37.5, 44.7, 55.0, 96.6, 104.8, 118.1, 128.6, 151.7, 159.2; MS (EI) m/z (rel intensity) 
57 (40), 205 (100), 220(50). 
 
2-(4-Bromo-3-methoxyphenyl)-2-methylheptane (9) 
To a solution of 0.281 g (1.27 mmol) of 13 in 0.5 mL of glacial acetic acid was slowly added 
0.065 mL (1.27 mmol) of bromine in 0.5 mL of acetic acid at ambient temperature. The solution 
was stirred for 2 h at ambient temperature, diluted with 5 mL of water and 3 mL of aqueous 
NaHCO3. The reaction mixture was extracted with two portions of ether and the ethereal extracts 
were washed with brine, dried (MgSO4), and concentrated in vacuo. The resultant orange oil was 
purified by flash chromatography (petroleum ether/ether, 9:1) to give 0.201g (79%) of 2-(4-
bromo-3-methoxyphenyl)-2-methylheptane (9) as a colorless oil; 1H NMR (500 MHz, CDCl3) δ 
0.87 (t, J = 7.0 Hz, 3H), 0.96-1.11 (m, 2H), 1.12-1.24 (m, 4H), 1.25 (s, 6H), 1.60 (t, J = 6, 2H), 
3.90 (s, 3H), 6.81 (dd, J = 2.2, 2 Hz, 1H), 6.84 (d, J = 2.2 Hz, 1H); 7.43 (d, J = 8 Hz, 1H); 13C 
NMR (125.77 MHz, CDCl3) δ 14.1, 22.5, 24.3, 28.9, 29.7, 32.5, 37.9, 44.5, 56.1, 110.1, 119.7, 
132.5, 151.1, 155.4; MS (EI) m/z (rel intensity) 91 (80), 148 (90), 199 (70), 227 (94), 298 (60). 
 
3-[2-Methoxy-4-(1,1-dimethylhexyl)phenyl]cyclohex-2-en-1-one (15) 
To a solution of 0.100g (0.336 mmol) of 2-(4-bromo-3-methoxyphenyl)-2-methylheptane (9) in 
3 mL of dry THF at -78 °C under argon was added 0.16 mL (0.403 mmol, 2.5 M solution in 
cyclohexane) of n-butyllithium and the mixture was stirred for 30 min. A solution of 0.048 g 
(0.336 mmol) of 3-ethoxycyclohex-en-1-one in 2 mL of dry THF was added dropwise and the 
solution was heated for 4 h at reflux. After cooling to ambient temperature the reaction was 
diluted with 15 mL of 10% aqueous HCl, stirred for 30 min and extracted with two portions of 
ether. The combined ethereal layers were washed with saturated aqueous NaHCO3, brine, dried 
(MgSO4) and concentrated in vacuo. The residue was chromatographed (petroleum ether/ether, 
3:2) to give 0.075 g (71%) of 15 as a yellow oil: 1H NMR (500 MHz, CDCl3) δ 0.82 (t, J = 7.0 
Hz, 3H), 0.98-1.26 (m, 6H), 1.27 (s, 6H), 1.59 (t, J = 6.0, 2H), 2.05-2.13 (m, 2H), 2.21-2.29 (m, 
2H), 2.74 (t, J = 5.8 Hz, 2H), 3.86 (s, 3H), 6.22 (s, 1H), 6.85 (s, 1H), 6.91 (d, J = 8.0 Hz, 1H), 
7.13 (d, J = 8 Hz, 1H); 13C NMR (125.77 MHz, CDCl3) δ 14.1, 22.6, 24.4, 24.6, 28.9, 29.7, 32.4, 
34.8, 37.2, 38.6, 44.7, 55.4, 112.9, 118.2, 120.4, 126.2, 133.2.2, 153.7, 155.2, 156.1, 199.6 : MS 
(EI). m/z (rel intensity) 243 (100), 314 (16). 
 
3-[2-Methoxy-4-(1,1-dimethylhexyl)phenyl]cyclohexanone (17) 
To 20 ml of liquid ammonia at -78 °C was added 0.004 g (0.579 g atom) of lithium shot and the 
solution was stirred for 10 min. A solution of 0.072 g (0.23 mmol) of 3-[2-methoxy-4-(1,1-
dimethylhexyl)phenyl]cyclohex-2-en-1-one (15) in 25 mL of dry THF was slowly added and the 
mixture was stirred at -78 °C for 30 min. The reaction was quenched by the addition of NH4Cl 
and the ammonia was evaporated at ambient temperature. The mixture was diluted with 10 mL 
of H2O and extracted with two portions of ether. The ethereal extracts were washed with brine, 
dried (MgSO4) and concentrated in vacuo. The yellow oil was purified by flash chromatography 
(petroleum ether/ether, 3:2) to give 0.056 g (78%) of 17 as a colorless oil: 1H NMR (500 MHz, 
CDCl3) δ 0.82 (t, J = 7.1 Hz, 3H), 1.01-1.27 (m, 6H), 1.28 (s, 6H), 1.53-1.60 (m, 2H), 1.71-1.81 
(m, 1H), 1.81-1.89 (m, 1H), 2.05-2.14 (m, 1H), 2.12-2.18 (m, 1H), 2.33-2.42(m, 1H), 2.42-2.48 
(m, 1H), 2.48-2.56 (m, 1H), 2.57-2.63 (m, 1H), 2.99 (dddd, J =3.8, 3.9, 11.9, 11.9 Hz, 1H), 3.84 
(s, 3H) 7.14 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H); 13C NMR (125.77 MHz, CDCl3) δ 
14.1, 22.5, 24.3, 25.6, 28.9, 32.5, 32.8, 37.4, 41.2, 44.2, 44.6, 49.0, 55.4, 113.3, 119.1, 126.2, 
126.6, 148.2, 159.6, 211.4 : MS (EI). m/z (rel intensity) 60 (25), 245 (100), 316 (17). 
 
(1R*,3S*)3-[2-Methoxy-4-(1,1-dimethylhexyl)phenyl]cyclohexanol (JWH 440, 7) 
To a solution of 0.054 g (0.17 mmol) of 3-[2-methoxy-4-(1,1-
dimethylhexyl)phenyl]cyclohexanone (17) in 6 mL of dry ethanol at 0 °C, was slowly added 
0.056 g (0.177 mmol) of NaBH4. The mixture was warmed to ambient temperature, stirred for 2 
h and quenched by the addition of 10 mL of 10% HCl. The solution was extracted with two 
portions of ether and the ethereal extracts were washed with saturated NaHCO3, brine, dried 
(MgSO4) and concentrated in vacuo. The yellow oil was chromatographed (petroleum 
ether/ether, 1:1) to give 0.038 g (68%) of JWH 440 (7) as a colorless oil; 1H NMR (500 MHz, 
CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H), 1.01-1.28 (m, 6H), 1.29 (s, 6H), 1.45-1.52 (m, 2H), 1.57-1.63 
(m, 4H), 1.78-1.92 (m, 2H), 2.04-2.19 (m, 2H), 2.99 (t, J = 12.0 Hz, 1H), 3.75-3.83 (m, 1H), 
3.81 (s, 3H), 7.84 (s, 1H), 6.87 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 8 Hz, 1H); 13C NMR (125.77 
MHz, CDCl3) δ 14.1, 22.6, 24.4, 24.6, 28.9, 29.7, 31.9, 32.6, 34.9, 35.6, 37.7, 42.1, 44.7, 55.4, 
71.3, 108.4, 117.9, 125.9, 131.2, 148.9, 156.4; MS (EI). m/z (rel intensity) 233 (33), 301 (65), 
319 (99); HRMS calcd for C21H35O2 319.2637, found 319.2629. 
 
(1S*,3S*)3-[2-Methoxy-4-(1,1-dimethylhexyl)phenyl]cyclohexanol (JWH 442, 19) 
To a solution of 0.020 g (0.063 mmol) of 3-[2-methoxy-4-(1,1-
dimethylhexyl)phenyl]cyclohexanone (17) in 1 mL of dry THF at -78 °C was added 0.27 mL 
(0.266 mmol, 1.0 M solution in THF) of L-Selectride and the mixture was stirred for 3 h, 
warmed to ambient temperature and stirred for 4 h. To the reaction mixture was added 4 mL of 
H2O, 3 mL of ethanol, 1 ml of 1 M aqueous NaOH and 1 mL of 30% aqueous H2O2. The 
reaction mixture was stirred for 30 min, extracted with two portions of ether and the ethereal 
layers were washed with brine, dried (MgSO4), and concentrated in vacuo. The yellow oil was 
purified by flash chromatography (petroleum ether/ether, 1:1) to give 0.011 g (55%) of JWH 442 
(19); 1H NMR (500 MHz) δ 0.88 (t, J = 7.0 Hz, 3H), 1.01-1.28 (m, 6H), 1.29 (s, 6H), 1.45-1.52 
(m, 2H), 1.57-1.63 (m, 4H), 1.78-1.92 (m, 2H), 2.04-2.19 (m, 2H), 3.37 (t, J = 12.0 Hz, 1H), 
4.24 (bs, 1H), 3.81 (s, 3H), 6.83 (s, 1H), 6.87 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H); 13C 
NMR (125.77 MHz, CDCl3) δ 14.1, 22.6, 24.4, 24.6, 28.9, 29.7, 31.9, 32.4, 34.9, 35.6, 37.7, 
42.1, 44.7, 55.4, 67.2, 108.4, 117.9, 125.8, 131.9, 148.7, 156.4; MS (EI) m/z (rel intensity) 233 
(33), 301 (65), 319 (99); HRMS calcd for C21H35O2 319.2637, found 319.2630. 
 
(1R*,3S*)3-[2-Methoxy-4-(1,1-dimethylheptyl)phenyl]cyclohexanol (JWH-441, 8) 
2-(3,5-dihydroxyphenyl)-2-methyl octane, provided by Norac Pharma, was converted to 
1R*,3S*)3-[2-methoxy-4-(1,1-dimethylheptyl)phenyl]cyclohexanol (8) by the procedure 
described for the synthesis of JWH-440. From 2.2 g (9.31 mmol) of 2-(3,5-dihydroxyphenyl)-2-
methyl octane there was obtained 0.126 g (5.7% for eight steps) of pure JWH-441 after flash 
chromatography (petroleum ether/ether, 1:1); 1H NMR (500 MHz) δ 0.89 (t, J = 7.0 Hz, 3H), 
1.01-1.28 (m, 8H), 1.29 (s, 6H), 1.45-1.52 (m, 4H), 1.57-1.63 (m, 2H), 1.79-1.94 (m, 2H), 2.03-
2.17 (m, 2H), 2.99 (t, J = 12.0 Hz, 1H), 3.74-3.83 (m, 1H), 3.82 (s, 3H), 6.83 (s, 1H), 6.87 (d, J = 
8.0 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 13C NMR (125.77 MHz, CDCl3) δ 14.1, 22.7, 24.6, 24.7, 
28.9, 29.7, 30.0, 31.9, 34.9, 35.6, 37.7, 42.1, 44.7, 55.4, 71.3, 108.4, 118.0, 125.8, 131.6, 148.9, 
156.8; MS (EI). m/z (rel intensity) 247 (18), 315 (43), 333 (99); HRMS calcd for C22H37O2 
333.2794, found 333.2687. 
 
Receptor Binding Experiments 
Materials. Frozen whole brains of male Sprague-Dawley rats were obtained from Harlan 
(Dublin, VA). CP-55,940 was provided by Pfizer (Groton, CT). [3H]CP-55,940 was purchased 
from NEN Life Science Products, Inc. (Boston, MA). Lipofectamine reagent was purchased from 
Life Technologies (Gaithersburg, MD). Human CB2 cDNA was provided by Dr. Sean Munro 
(MRC Lab, Cambridge, UK). DMEM and geneticin was purchased from (GIBCO BRL, Grand 
Island, NY). Fetal clone II was purchased from Hyclone Laboratories, Inc. (Logan, UT). Aquasil 
was purchased from Pierce (Rockford, IL). GF/C glass-fiber filters (2.4 cm) were purchased 
from Baxter (McGaw Park, IL). Polyethylenimine and bovine serum albumin were purchased 
from Sigma Chemical Co. (St. Louis, MO). Scintillation vials and Budget Solve scintillation 
fluid were purchased from RPI Corp. (Mount Prospect, IL). 
 
Development of hCB2-CHO Cell Line. Chinese hamster ovary cells were maintained in 
Dulbecco's modified Eagle's medium (DMEM) with 10% fetal clone II and 5% CO2 at 37 °C in a 
Forma incubator. Cell lines were created by transfection of CB2pcDNA3 into CHO cells by the 
Lipofectamine reagent. Stable transformants were selected in growth medium containing 
geneticin (1 mg/mL, reagent). Colonies of about 500 cells were picked (about 2 weeks post 
transfection) and allowed to expand, then tested for expression of receptor mRNA by northern 
blot analysis. Cell lines containing moderate to high levels of receptor mRNA were tested for 
receptor binding properties. Transfected cell lines were maintained in DMEM with 10% fetal 
clone II plus 0.3-0.5 mg/mL geneticin and 5% CO2 at 37 °C in a Forma incubator. 
 
Membrane Preparation. hCB2-CHO cells were harvested in phosphate-buffered saline 
containing 1 mM EDTA and centrifuged at 500g. Cell pellets (for CB2) or whole rat brains (for 
CB1) were homogenized in 10 mL of solution A (50 mM Tris-HCl, 320 mM sucrose, 2 mM 
EDTA, 5 mM MgCl2, pH 7.4). The homogenate was centrifuged at 1,600 × g (10 min), the 
supernatant saved, and the pellet washed three times in solution A with subsequent 
centrifugation. The combined supernatants were centrifuged at 100,000 × g (60 min). The (P2 
membrane) pellet was resuspended in 3 mL of buffer B (50 mM Tris-HCl, 1 mM EDTA, 3 mM 
MgCl2, pH 7.4) to yield a protein concentration of approximately 1 mg/mL. The tissue 
preparation was divided into equal aliquots, frozen on dry ice, and stored at -70 °C. 
 
Competition Binding Assays 
CB1 Assay. [3H]CP-55,940 binding to P2 membranes was conducted as described elsewhere,49 
except whole brain (rather than cortex only) was used. CP-55,940 and all cannabinoid analogs 
were prepared by suspension in assay buffer from a 1 mg/mL ethanolic stock without 
evaporation of the ethanol (final concentration of no more than 0.4%). Displacement curves were 
generated by incubating drugs with 1 nM of [3H]CP-55,940. [3H]CP-55,940 bound to rat brain 
membranes with a KD value of 0.68 ± 0.07 nM and a Bmax value of 1.7 ± 0.11 pmol/mg. The 
assays were performed in triplicate, and the results represent the combined data from three 
individual experiments. 
 
CB2 Assay. Binding was assayed by a modification of Compton et al.44 CP-55,940 and all 
cannabinoid analogs were prepared by suspension in assay buffer from a 1 mg/mL ethanolic 
stock without evaporation of the ethanol (final concentration of no more than 0.4%). The 
incubation was initiated by the addition of 40-50 μg membrane protein to silanized tubes 
containing [3H]CP-55,940 (102.9 Ci/mmol) and a sufficient volume of buffer C (50 mM Tris-
HCl, 1 mM EDTA, 3 mM MgCl2, and 5 mg/mL fatty acid free BSA, pH 7.4) to bring the total 
volume to 0.5 mL. The addition of 1 μM unlabelled CP-55,940 was used to assess nonspecific 
binding. Following incubation (30 °C for 1 hour), binding was terminated by the addition of 2 
mL of ice cold buffer D (50 mM Tris-HCl, pH 7.4, plus 1 mg/mL BSA) and rapid vacuum 
filtration through Whatman GF/C filters (pretreated with polyethyleneimine (0.1%) for at least 2 
hours). Tubes were rinsed with 2 mL of ice cold buffer D, which was also filtered, and the filters 
subsequently rinsed twice with 4 mL of ice cold buffer D. Before radioactivity was quantitated 
by liquid scintillation spectrometry, filters were shaken for 1 hr in 5 mL of scintillation fluid. 
[3H]CP-55,940 bound to hCB2-CHO cells membranes with a KD value of 0.45 ± 0.07 nM and a 
Bmax value of 2.93 ± 0.06 pmol/mg. 
 
Data Analysis. Competition assays were conducted with 1 nM [3H]CP-55,940 and 6 
concentrations (0.1 nM to 10 μM displacing ligands). Displacement IC50 values were originally 
determined by unweighted least-squares linear regression of log concentration-percent 
displacement data and then converted to Ki values using the method of Cheng and Prusoff.50 All 
experiments were performed in triplicate and repeated 3-6 times. All data are reported as mean 
values ± SEM. 
 
Computational methods 
Conformational analysis. A conformational search for each ligand using the MCMM/LCMS 
method as implemented in Macromodel 9.6 (Schrödinger LLC, NY, USA) was conducted. The 
OPLS2005 forcefield was used with a distance dependent dielectric and nonbonded cutoffs of 
20Å, 8.0 Å, and 4.0 Å respectively for electrostatic, VdW, and H-bond interactions. 50,000 
structures were evaluated within a 10 kcal/mol window above the lowest energy structure found. 
All rotatable bonds were varied during the conformational search. Elimination of duplicate 
structures was performed by considering structures to be different if the maximum atom 
deviation for any pair of corresponding atoms exceeded 0.5 Å. 
 
CB2 Receptor Docking Studies. The C ring atoms of each ligand were superimposed on the 
AM841 C ring in our hCB2 receptor model.44 Modifications to ligand torsions were performed 
using interactive computer graphics in order to fit the compound into the AM841 binding site. 
Steric overlaps were eliminated using interactive computer graphics. AM841 was then removed 
from the complex in preparation for subsequent minimization. 
 
Ligand/CB2 Receptor Minimization. Minimization of the hCB2-receptor bundle-JWH 
compound complex was performed in Macromodel 9.6 (Schrödinger LLC, NY, USA) using the 
OPLS2005 forcefield with a distance dependent dielectric and nonbonded cutoffs of 20 Å, 8.0 Å, 
and 4.0 Å respectively for electrostatic, VdW, and H-bond interactions. All residues except 
D2.50(80), K3.28(109), and D(275) were neutralized during the minimization. To preserve the 
TMH backbone conformation, torsional restraints of 100 kcal/mol were applied to the phi, psi, 
and omega dihedrals of each CB2 TMH. To preserve the loop conformations, non-moving fixed 
atom restraints as implemented in Macromodel were applied to the loop backbone atoms. The 
full receptor/ligand complex was energy minimized with the Polak-Ribier conjugate gradient 
method until an energy gradient of 0.1 kcal/mol·Å2 was reached. Approximately 500 steps were 
required to reach the specified gradient since the receptor/ligand complex was already very near 
a minimum in each case. 
 
Energy Expense Assessments for Docked Ligands. To calculate the energy difference between 
the global minimum energy conformation of each compound and its final docked conformation 
after energy minimization of the ligand/receptor complex, single point energies of the final 
docked conformation and the global minimum structure were calculated using the OPLS2005 
forcefield. A distance dependent dielectric, 8.0 Å extended nonbonded cutoff, 20.0 Å 
electrostatic cutoff, and 4.0 Å H-bond cutoff were used in the calculation. 
 
Assessment of Pairwise Interaction Energies. After defining the atoms of a ligand in the final 
energy minimized CB2 R* complex as one group (group 1) and the atoms corresponding to a 
residue that lines the binding site in the final ligand/CB2 R* energy minimized complex as 
another group (group 2), Macromodel (version 9.6) was used to output the pair-wise interaction 
energy (coulombic and van der Waals) for a given pair of atoms. The pairs corresponding to 
group 1 (ligand) and group 2 (residue of interest) were then summed to yield the interaction 
energy between the ligand and that residue. A total interaction energy for each ligand with CB2 
R* was calculated by summing the pairwise interaction energies for all residues in the binding 
site of that ligand and adding to this sum, the conformational energy expense for the ligand (see 
5.12.4 above). 
 
CB1 Receptor Docking Studies. The C ring atoms of each ligand were superimposed on the 
HU-210 C ring in our hCB1 receptor model.47 Modifications to ligand torsions were performed 
using interactive computer graphics to attempt fitting each ligand into the HU-210 binding site. It 
was not possible to eliminate steric overlaps for any of these compounds. Therefore, no 
subsequent energy minimzation was performed. 
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